Waldenstroms Macroglobulinemia
Waldenstroms Macroglobulinemia Prognosis

Waldenstroms Macroglobulinemia Prognosis

The prognosis for sufferers of waldenstrom's macroglobulinemia symptoms can be varied and is more positive than similar disease multiple myeloma. Because waldenstrom's macroglobulinemia is such a rare disease there has not been much research done to identify the survival rates of patients diagnosed with the disease although there is a widely accepted average survival time. However there is now The International Prognostic Scoring System for Waldenstrom's Macroglobulinemia (IPSSWM) which is a predictive model which aims to help examine the long term outcomes of the disease. The average accepted survival time for those diagnosed with waldenstrom's macroglobulinemia is five to nine years after it is diagnosed. Because there are little initial symptoms people can live with this disease for many years prior to diagnosis.

IPSSWM

Waldenstrom's macroglobulinemia prognosis is influenced by a number of factors such as how advanced the disease is at diagnosis and how rapidly it is advancing. Age is also an influential factor with the prognosis being worse for older patients. There can be other negative factors for prognosis such as the presence of other conditions such as Raynaud's phenomenon which results in poor circulation and is a common complication among sufferers of waldenstrom's macroglobulinemia.

Some patients diagnosed with waldenstrom's macroglobulinemia can live for upwards of 25 years with few symptoms or complications. Waldenstrom's macroglobulinemia clinical trials are continuing to further our knowledge as to patients prognosis.